The international Lighthouse II clinical trial investigating the HIV drug Triumeq as a potential treatment for motor neuron disease (MND) has been halted early. An interim analysis showed that the drug did not improve survival for people with MND compared to placebo, leading to the decision to stop the trial.
Testing an antiviral drug
Lighthouse II, a global Phase 3 randomised, double-blind, placebo-controlled study, was a collaborative effort led by TRICALS in partnership with King’s College London and Macquarie University. It included more than 400 participants across 29 centres in Europe, the UK, Australia, and New Zealand.
Triumeq is an antiviral drug commonly used to treat HIV and was chosen for this study because it may affect human endogenous retroviruses (HERVs)—remnants of ancient viral infections in our DNA—which some researchers believe could play a role in MND.
Looking at the analysis
The trial included a planned interim analysis to assess whether the treatment demonstrated a measurable effect on survival, its primary endpoint. Unfortunately, the study concluded that Triumeq did not provide a survival benefit for people with MND compared to placebo.
As a result, the trial has been terminated, and all participants have been contacted and asked to stop taking the study drug immediately. A complete data analysis is currently underway and will be published in due course.
Professor Ammar Al-Chalabi, Co-Director of the UK MND Research Institute and UK Coordinating Investigator of Lighthouse II, said: “We wish to thank all of the patients, their families and the study teams who participated in the Lighthouse II study. While this result may be disappointing, without the people with MND who were willing to join the trial, we would not have been able to establish that this treatment is ineffective so quickly. We are grateful for their time, energy and determination to help the research effort to find treatments for this terrible disease.”
What does this mean?
Although Triumeq has not proven to be effective for MND, the results from Lighthouse II contribute valuable knowledge to the scientific community. Efforts are already underway to analyse the entire dataset, and future studies will continue to explore other promising therapeutic avenues.
The early closure of the Lighthouse II study, while a setback, is also a significant step forward in understanding which treatments are—and are not—effective for MND. This decision, based on the interim analysis, not only saves time and resources but also prevents further exposure of participants to an ineffective treatment. The UK MND Research Institute remains committed to supporting rigorous, collaborative research that brings us closer to effective therapies and, ultimately, a cure.
To stay informed about the latest MND research and contribute to the ongoing efforts, follow the UK MND Research Institute on social media or sign up for our newsletter. Your support and involvement are crucial to our mission of finding effective treatments for MND.
